Skip to Content

Drotrecogin Alfa (Activated) Injection

Last Updated: October 26, 2011
Status: Discontinued

Products Affected - Description

Xigris, Eli Lilly and Company
5 mg vial (NDC 00002-7561-01)
20 mg vial (NDC 00002-7559-01)

Reason for the Shortage

  • Lilly discontinued Xigris in October, 2011 due to failure of showing survival benefit in the PROWESS-SHOCK trial. Details of the Xigris withdrawal are available online.
  • Do not start any new patients on Xigris and discontinue treatment in patients currently receiving Xigris. Return all unused product to place of purchase.
  • Lilly was the only manufacturer of drotrecogin alfa.

Available Products


Estimated Resupply Dates

Eli Lilly and Company discontinued Xigris in October, 2011.

Related Shortages


October 26, 2011, University of Utah, Drug Information Service. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.